Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model

Journal of Evaluation in Clinical Practice

Volumn 18, Issue 2, 2012, Pages 247-255

  Patel, Jignesh J ^a   Mendes, Margaret A S ^a,b,c   Bounthavong, Mark ^a,b,c   Christopher, Melissa L D ^a,b,c   Boggie, Daniel ^a,b,c   Morreale, Anthony P ^a,b,c  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF THE PACIFIC   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

age related macular degeneration; bevacizumab; cost effectiveness analysis; cost utility analysis; ranibizumab

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

ARTICLE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG EFFICACY; DRUG SAFETY; GOVERNMENT; HEALTH CARE COST; HUMAN; MEDICARE; PRIORITY JOURNAL; QUALITY OF LIFE; RETINA MACULA AGE RELATED DEGENERATION; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; UNITED STATES; VISION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MACULAR DEGENERATION; MALE; MARKOV CHAINS; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; UNITED STATES;

EID: 84858139464     PISSN: 13561294     EISSN: 13652753     Source Type: Journal    
DOI: 10.1111/j.1365-2753.2010.01546.x     Document Type: Article

References (48)

1. Friedman, D. S., O'Colmain, B. J., Muñoz, B., Tomany, S. C., McCarty, C., de Jong, P. T., Nemesure, B., Mitchell, P., Kempen, J., & Eye Diseases Prevalence Research Group (2004) Prevalence of age-related macular degeneration in the United States. Archives of Ophthalmology, 122, 564-572.
2. Ivers, R. Q., Cumming, R. G., Mitchell, P., Simpson, J. M., &, Peduto, A. J., (2003) Visual risk factors for hip fractures in older people. Journal of the American Geriatrics Society, 51, 356-363.
3. Brody, B. L., Gamst, A. C., Williams, R. A., Smith, A. R., Lau, P. W., Dolnak, D., Rapaport, M. H., Kaplan, R. M., &, Brown, S. I., (2001) Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration. Ophthalmology, 108, 1893-1900.
4. Rovner, B. W., Casten, R. J., &, Tasman, W. S., (2002) Effect of depression on vision function in age-related macular degeneration. Archives of Ophthalmology, 120, 1041-1044.
5. Oneill, C., Jamison, J., McCulloch, D., &, Smith, D., (2001) Age-related macular degeneration: cost-of-illness issues. Drugs & Aging, 18, 233-241.
6. Javitt, J. C., Zhou, Z., &, Willke, R. J., (2007) Association between vision loss and higher medical care costs in Medicare beneficiaries costs are greater for those with progressive vision loss. Ophthalmology, 114, 238-245.
7. Brown, M. M., Brown, G. C., Sharma, S., Stein, J. D., Roth, Z., Campanella, J., &, Beauchamp, G. R., (2006) The burden of age-related macular degeneration: a value-based analysis. Current Opinion in Ophthalmology, 17, 257-266.
8. Ng, E. W., &, Adamis, A. P., (2005) Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Canadian Journal of Ophthalmology, 40, 352-368.
9. Otani, A., Takagi, H., Oh, H., Koyama, S., Ogura, Y., Matumura, M., &, Honda, Y., (2002) Vascular endothelial growth factor family and receptor expression in human choroidal neovascular membranes. Microvascular Research, 64, 162-169.
10. Rakic, J. M., Lambert, V., Devy, L., Luttun, A., Carmeliet, P., Claes, C., Nguyen, L., Foidart, J. M., Noël, A., &, Munaut, C., (2003) Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Investigative Ophthalmology & Visual Science, 44, 3186-3193.
11. Kliffen, M., Sharma, H. S., Mooy, C. M., Kerkvliet, S., &, de Jong, P. T., (1997) Increased expression of angiogenic growth factors in age-related maculopathy. The British Journal of Ophthalmology, 81, 154-162.
12. Wells, J. A., Murthy, R., Chibber, R., Nunn, A., Molinatti, P. A., Kohner, E. M., &, Gregor, Z. J., (1996) Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation. The British Journal of Ophthalmology, 80, 363-366.
13. Gragoudas, E. S., Adamis, A. P., Cunningham, E. T. Jr, Feinsod, M., Guyer, D. R., & VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group (2004) Pegaptanib for neovascular age-related macular degeneration. The New England Journal of Medicine, 351, 2805-2816.
14. Chakravarthy, U., Adamis, A. P., Cunningham, E. T. Jr, Goldbaum, M., Guyer, D. R., Katz, B., Patel, M., & VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group (2006) Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology, 113, 1508-1533.
15. Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., Kim, R. Y., & MARINA Study Group (2006) Ranibizumab for neovascular age-related macular degeneration. The New England Journal of Medicine, 355, 1419-1431.
16. Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., Schneider, S., & ANCHOR Study Group (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. The New England Journal of Medicine, 355, 1432-1444.
17. Rosenfeld, P. J., Moshfeghi, A. A., &, Puliafito, C. A., (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surgery, Lasers & Imaging, 36, 331-335.
18. Yoganathan, P., Deramo, V. A., Lai, J. C., Tibrewala, R. K., &, Fastenberg, D. M., (2006) Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration. Retina, 26, 994-998.
19. Aisenbrey, S., Ziemssen, F., Völker, M., Gelisken, F., Szurman, P., Jaissle, G., Grisanit, S., &, Bartz-Schmidt, K. U., (2007) Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology, 245, 941-948.
20. Spaide, R. F., Laud, K., Fine, H. F., Klancnik, J. M. Jr, Meyerle, C. B., Yannuzzi, L. A., Sorenson, J., Slakter, J., Fisher, Y. L., &, Cooney, M. J., (2006) Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina, 26, 383-390.
21. Avery, R. L., Pieramici, D. J., Rabena, M. D., Castellarin, A. A., Nasir, M. A., &, Giust, M. J., (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology, 113, 363-372.
22. Rich, R. M., Rosenfeld, P. J., Puliafito, C. A., et al,. (2006) Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina, 26, 495-511.
23. Emerson, M. V., Lauer, A. K., Flaxel, C. J., Wilson, D. J., Francis, P. J., Stout, J. T., Emerson, G. G., Schlesinger, T. K., Nolte, S. K., &, Klein, M. L., (2007) Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina, 27, 439-444.
24. Madhusudhana, K. C., Hannan, S. R., Williams, C. P., Goverdhan, S. V., Rennie, C., Lotery, A. J., Luff, A. J., &, Newsom, R. S., (2007) Intravitreal bevacizumab (Avastin) for the treatment of choroidal neovascularization in age-related macular degeneration: results from 118 cases. The British Journal of Ophthalmology, 91, 1716-1717.
25. Lazic, R., &, Gabric, N., (2007) Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology, 114, 1179-1185.
26. Bashshur, Z. F., Haddad, Z. A., Schakal, A., Jaafar, R. F., Saab, M., &, Noureddin, B. N., (2008) Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. American Journal of Ophthalmology, 145, 249-256.
27. Fleming, T., (ed.) (2007) Redbook: Pharmacy's Fundamental Reference. Montvale, NJ: Thomson PDR.
28. Smith, D. H., Fenn, P., &, Drummond, M., (2004) Cost effectiveness of photodynamic therapy with verteporfin for age related macular degeneration: the UK case. The British Journal of Ophthalmology, 88, 1107-1112.
29. Brown, G. C., Brown, M. M., Brown, H. C., Kindermann, S., &, Sharma, S., (2007) A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration. Ophthalmology, 114, 1170-1178.
30. Brown, M. M., Brown, G. C., Brown, H. C., &, Peet, J., (2008) A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration. Ophthalmology, 115, 1039-1045.
31. Wolowacz, S. E., Roskell, N., Kelly, S., Maciver, F. M., &, Brand, C. S., (2007) Cost effectiveness of pegaptanib for the treatment of age-related macular degeneration in the UK. Pharmacoeconomics, 25, 863-879.
32. Raftery, J., Clegg, A., Jones, J., Tan, S. C., &, Lotery, A., (2007) Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness. The British Journal of Ophthalmology, 91, 1244-1246.
33. Drummond, M. F., Sculpher, M. J., Torrance, G. W., O'Brien, B. J., &, Stoddart, G. L., (2005) Methods for the Economic Evaluation of Health Care Programmes, 3rd edn. Oxford: Oxford University Press.
34. Hoyert, D. L., Heron, M. P., &, Murphy, S. L., (2006) Deaths: Final Data for 2003. National Vital Statistics Reports (Vol. 54 No. 13). Hyattsville, MD: National Center for Health Statistics.
35. Zhou, S., Javitt, J. C., Zlateva, G., et al,. (2006) Evaluating the risk of mortality for exudative (wet) AMD patients compared to a control group. Investigative Ophthalmology & Visual Science, 47, E-abstract 2213.
36. Brown, G. C., Sharma, S., Brown, M. M., &, Kistler, J., (2000) Utility values and age-related macular degeneration. Archives of Ophthalmology, 118, 47-51.
37. Veterans Affairs San Diego Healthcare System Decision Support System cost data (2007) Data on file. [last accessed October 2007].
38. Centers for Medicare and Medicaid Services physician fee schedule overview (2006) Available at: http://www.cms.gov/PhysicianFeeSched (last accessed 15 October 2007).
39. ASC procedure list-2006 (2006) Centers for Medicare and Medicaid Services ambulatory surgical centers (ASC) center. Available at: http://www.cms.gov/ ASCPayment/09-archive.asp#TopOfPage (last accessed 15 October 2007).
40. Centers for Medicare and Medicaid Services 2006. ASP pricing files (2006) Available at: http://www.cms.gov/McrPartBDrugAvgSalesPrice/02-aspfiles.asp (last accessed 15 October 2007).
41. Briggs, A., &, Sculpher, M., (1998) An introduction to Markov modelling for economic evaluation. Pharmacoeconomics, 13, 397-409.
42. Briggs, A. H., (2000) Handling uncertainty in cost-effectiveness models. Pharmacoeconomics, 17, 479-500.
43. Fenwick, E., O'Brien, B. J., &, Briggs, A., (2004) Cost-effectiveness acceptability curves-facts, fallacies and frequently asked questions. Health Economics, 13, 405-415.
44. Algvere, P. V., Steén, B., Seregard, S., &, Kvanta, A., (2008) A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations. Acta Ophthalmologica Scandinavica, 86, 482-489.
45. Arias, L., Caminal, J. M., Casas, L., Masuet, C., Badia, M. B., Rubio, M., Pujol, O., &, Arruga, J., (2008) A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology, 92, 1636-1641.
46. Fong, K. C., Kirkpatrick, N., Mohamed, Q., &, Johnston, R. L., (2008) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration using a variable frequency regimen in eyes with no previous treatment. Clinical & Experimental Ophthalmology, 36, 748-755.
47. Binder, S., & Ludwig Boltzmann Institute for Retinology and Biomicroscopic Lasersurgery. A Randomized Observer and Subject Masked Trial Comparing the Visual Outcome after Treatment with Ranibizumab or Bevacizumab in Patients with Neovascular Age-Related Macular Degeneration Multicenter Anti VEGF Trial in Austria (MANTA). ClinicalTrials.gov Identifier: NCT00710229. Available at: (last accessed 28 September 2009).
48. Martin, D. F., Fine, S. L., Maguire, M. G., Jaffe, G., Grunwald, J. E., & The National Eye Institute. Comparison of Age-Related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial (CATT). ClinicalTrials.gov Identifier: NCT00593450. Available at: (last accessed 28 September 2009).